diagnosis

MSBase and icometrix have joined efforts in a large-scale project to identify imaging markers of multiple sclerosis (MS) that could help diagnose the disease in its early stages. The combination of magnetic resonance imaging (MRI) information collected from MS patients with clinical information from the MSBase Registry can offer new insights in disease progression, potentially leading to new predictive tools for MS. It may also promote more standardized use of imaging measures in clinical practice. With more than 52,000 MS patients, the MSBase Registry is an international database committed to collecting patients’ information as well as sharing, tracking and evaluating overall outcome data in MS and other neurological conditions. Until now, the MSBase Registry included only descriptive information regarding patients' imaging analysis results, with no access to full imaging data. This joint, large-scale project will include MRI scan data routinely acquired in clinical setting taking advantage of icometrix’s software platform, MSmetrix. “We wish to unlock the power of MRI for personalized monitoring in MS," Helmut Butzkueven, director of MSBase, said in a press release. "The MSBase Scientific Leadership group has selected MRI integration as the top strategic priority for MSBase. We believe that already conducted MRI scans represent an enormous missed opportunity, because advanced measurements to assess change over time from these scans are not currently in practical use.” Butzkueven said MSBase "will test the predictive power of this unlocking of MRI data in the first phase," with a total of 10,000 MRI data points in at least 3,000 MS patients from all over the world. The project is expected to identify disease progression markers that could help detect early signs of MS by MRI evaluation. This investigator-initiated collaboration between icometrix and the MSBase Foundation is being supported by three global pharmaceutical giants: Novartis, Biogen and Roche. “MRI measures play an essential part in the complex puzzle of MS,” said Danny Bar Zohar, global head of neuroscience development at Novartis. “Partnering with MS Base and icometrix in this exciting project will bring the acquisition of high-quality real world data to the next level, ultimately improving the outcome of people living with MS.”

The National Institutes of Health (NIH) has awarded a $1 million grant to IQuity, a Nashville-based company looking into novel RNA targets that ultimately benefit patients with multiple sclerosis (MS) and other autoimmune disorders. The NIH grant is part of the institute’s Small Business Innovation Research (SBIR) program.

The MS Wire is adding a third weekly item, beginning today. It’s a list of several news items that appeared in MS News Today over the preceding week and that caught my eye. Axim Signs Deal to Advance Clinical Trials of Cannabis-based MedChew Rx Gum to…

A significant percentage of multiple sclerosis (MS) patients struggle with improper diagnoses and ineffective treatments, a national survey of more than 5,300 patients found. The fifth annual survey, “MS in America 2017,” was conducted by Health Union between Jan. 25 and March 1, 2017. It was released through the…

Patients with multiple sclerosis (MS) may be developing the disease for up to five years before the first clinical diagnosis is made, a study has found. The study, “Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study,” was published…

Editor’s note: Marking the second MS diagnosis anniversary of our columnists in one week, Judy Lynn writes about the “Anniversary Effect.” This week marks the 14th anniversary of my MS diagnosis. That day, March 27, 2003, is etched clearly in my mind.  Ask me about anything else I was doing…

On March 27, 2013, my primary care physician called me about MRI results from the day before. He and the radiologist concurred; they had found evidence of brain lesions consistent with multiple sclerosis. Following protocol, he sent me to the best specialist in Seattle to confirm diagnosis. His was a preliminary diagnosis. In the…

What is benign MS? Does it even exist? Certainly it is not one of the types of the disease often listed as making up the multiple sclerosis family. It is a term that is surrounded by controversy,…

Kinesiology professor Richard van Emmerik and his colleagues at the University of Massachusetts Amherst recently received a two-year $833,000 grant from the U.S. Department of Defense to create an improved diagnostic test for multiple sclerosis (MS). The scientists expects their research to help an estimated 2.3 million people worldwide who live with…

Molecular diagnostics startup IQuity is introducing a pioneering blood test that speeds up multiple sclerosis (MS) diagnosis to just seven days. Previously, this process could take up to months or years. IQuity, based in Nashville, Tennessee, began working on its new IsolateMS blood test in January 2016, after receiving $2…

The MS world lost a very important person on Feb. 8. Britain’s Sir Peter Mansfield, Nobel Laureate, passed away at the age of 83. For most of us, his name means little, but his work revolutionized the way multiple sclerosis is diagnosed, and the way progression of the disease…

Scientists have discovered the first blood biomarker for multiple sclerosis (MS) –  a chemical identifier in the blood. The discovery should lead to a simple blood test that makes it quicker and easier to follow the course of MS, a debilitating disease of the central nervous system affecting around 2.3 million people…

MicroRNAs in the blood could serve as biomarkers to monitor the progression of multiple sclerosis (MS), as well as help identify which mechanisms are at play in each patient, such as inflammation and tissue damage, according to new research. The findings were reported in the study, “Association Between Serum…

Progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients treated with Tysabri (natalizumab) is linked to better outcomes if the condition does not give rise to actual symptoms and is diagnosed early. Limited brain lesions and more protective immune responses were also seen in patients who fared better, but researchers…

I’m sure all of us with multiple sclerosis have had at least one magnetic resonance imaging (MRI) scan. Most likely, more than one. MRIs are designed to scan and provide detailed pictures of the body, the brain included. The test can reveal scars (plaque lesions) on the brain and the…

Royal Philips recently announced the introduction of the IntelliSpace Portal 9.0, the latest edition of its advanced comprehensive visual analysis and quantification platform for neurological disorders. The platform was presented at the 2016 Radiological Society of North America Annual Meeting (RSNA), taking place through Dec. 2 in Chicago. Currently a work in…

Royal Philips will introduce a new suite of magnetic resonance (MR)-based software applications at the upcoming Radiological Society of North America’s 102nd Scientific Meeting and Annual Assembly (RSNA 2016; #RSNA16) Nov. 27 to Dec. 2 in Chicago. Philips’ Ingenia family of digital MRI systems provides radiologists with a unique set…

  I am thankful for a lot of things in my life and my multiple sclerosis (MS) diagnosis is one of them. Before learning it was MS, I was on a very long roller-coaster ride of unexplained symptoms. Test after test came back normal. Yet, I still had weak…

Quanterix and UmanDiagnostics are working to advance an assay capable of detecting neuron damage in a blood sample — a tool that could aid in the early diagnosis of multiple sclerosis (MS) and other neurodegenerative conditions. The collaboration brings Quanterix’ Simoa technology together with Uman’s antibodies against neurofilament light (Nf-L) — a…

Advances in brain imaging are making it possible to visualize early and ongoing events in multiple sclerosis (MS) — beginning with the first signs of inflammation caused by immune cells entering the brain. Should the new technique become available to physicians, it likely will not only allow for more precise diagnoses, but…

Researchers at McGill University Health Centre (MUHC) in Canada developed a new tool to diagnose cachexia — also called wasting syndrome. It’s characterized by weight loss, muscle atrophy, fatigue, weakness, and a significant loss of appetite in someone who is not trying to lose weight, mainly in cancer patients. The tool may also…

A newly discovered potential biomarker of multiple sclerosis (MS) may help to distinguish between people who will go on to have less severe disease and those in whom the disease will progress, researchers at Linköping University in Sweden report. The biomarker’s discovery came through an investigation into the immune system of MS…

In MS patient columnist Teresa Wright-Johnson’s debut column on Multiple Sclerosis News Today, she introduces herself and discusses the pain and uncertainty of her diagnosis. She also shares how spirituality and reflection are leading her to overcome the diagnosis and move forward. Hello everyone! Thank you for allowing me the opportunity to share…

Two presentations at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2016 Congress, now underway in London, underscored the value of measures of neurodegeneration in the eye in predicting a patient’s future disability. Peter Calabresi with the Johns Hopkins School of Medicine opened the session with the presentation, “Tools for…

Early detection is very important for any disease diagnosis. With Multiple Sclerosis, it gives you the opportunity to start a treatment plan early that may help with slowing the progression of the disease. Symptoms of MS vary widely from person to person and can closely mimic other disease symptoms. Lesions don’t always…

MicroRNAs present in the blood show promise as potential biomarkers of multiple sclerosis (MS), a new study suggests. The study, titled “Comprehensive Evaluation Of Serum MicroRNAs As Biomarkers In Multiple Sclerosis,” was published by Keren Regev, MD, and colleagues in the journal Neurology. Human DNA contains…

Patients with a number of common conditions — some neurological and some autoimmune, but others not — are being mistakenly diagnosed with multiple sclerosis (MS) because of difficulties in correctly determining this disease and, possibly, pressure to begin treatment early in the disease’s course, according to a recent study published in the…

Scientists at Russia’s Tomsk Polytechnic University (TPU) and Siberian State Medical University (SSMU), both in Tomsk, have developed a diagnosis system for neurodegenerative diseases in the early stages. The system uses virtual reality (VR) technology to immerse a subject in a virtual environment during functional tests designed to detect early symptoms of…

Being diagnosed with MS can be more than a bit of a shock at first. Yes, you finally know what you’ve got, what all those symptoms you’ve having mean, and you have heard what your neurologist told you. Well, you may have heard, but you didn’t take it in…

There can be absolutely no excuse for anyone experiencing the first signs and symptoms of neurological conditions like MS having to wait a long time to see an appropriate specialist, such as a neurologist. Delays in seeing specialists is a complaint often heard from patients in various countries, and it…